Skip to Content

Orchestra BioMed Holdings Inc OBIO

Morningstar Rating
$5.13 −0.10 (1.91%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

OBIO is trading at a 157% premium.
Price
$5.20
Fair Value
$23.42
Uncertainty
Extreme
1-Star Price
$48.52
5-Star Price
$1.91
Economic Moat
Ychzq
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OBIO is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$5.23
Day Range
$4.875.56
52-Week Range
$4.2217.35
Bid/Ask
$4.96 / $5.15
Market Cap
$183.59 Mil
Volume/Avg
40,334 / 40,669

Key Statistics

Price/Earnings (Normalized)
Price/Sales
83.21
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
56

Comparables

Valuation

Metric
OBIO
ATEC
ANIK
Price/Earnings (Normalized)
128.20
Price/Book Value
3.2740.901.82
Price/Sales
83.212.782.22
Price/Cash Flow
20.17
Price/Earnings
OBIO
ATEC
ANIK

Financial Strength

Metric
OBIO
ATEC
ANIK
Quick Ratio
7.211.373.50
Current Ratio
7.342.395.26
Interest Coverage
−9.60
Quick Ratio
OBIO
ATEC
ANIK

Profitability

Metric
OBIO
ATEC
ANIK
Return on Assets (Normalized)
−35.16%−9.36%0.92%
Return on Equity (Normalized)
−51.40%1.13%
Return on Invested Capital (Normalized)
−50.12%−9.08%0.17%
Return on Assets
OBIO
ATEC
ANIK
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRKnqpjjlbdPnyb$586.3 Bil
VRTX
Vertex Pharmaceuticals IncVbwznfxklXbsxy$115.1 Bil
REGN
Regeneron Pharmaceuticals IncRtwjdvhnvFngvlnk$108.2 Bil
MRNA
Moderna IncLdtwgbrwcRkhl$54.0 Bil
BNTX
BioNTech SE ADRPhcrklbwrYwwy$21.8 Bil
ARGX
argenx SE ADRHfnkrltwDjwk$21.6 Bil
ALNY
Alnylam Pharmaceuticals IncQjqjzrlyYskyl$18.9 Bil
BMRN
Biomarin Pharmaceutical IncSwqwzlgkJgkjfwy$14.6 Bil
INCY
Incyte CorpNghkfvpCpfzp$12.9 Bil
RPRX
Royalty Pharma PLC Class ABmxcrqzvcWssdgv$12.3 Bil

Sponsor Center